Mason Foundation-funded ME/CFS biobank

In August 2019, we were excited to announce that Emerge Australia is to be a key part of the team awarded a $1million grant from philanthropic trust, the Mason Foundation, to establish the first Australian ME/CFS biobank and patient registry.

The grant consists of two components: the biobank and patient registry, and a research project that uses the samples stored in the biobank. Taken together, these two components, which make up this landmark project, will help biomedical researchers advance our understanding of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

The Mason Foundation-funded biobank and patient registry will be led by Emerge Australia, partnering with Solve ME/CFS Initiative (SMCI) in the US, and the UK ME Biobank (UKMEB), making it a global project. This innovative project will make use of existing Australian Red Cross Lifeblood resources, and will also benefit from the infrastructure of the UKMEB and resources being developed by SMCI. The biobank will store blood samples of ME/CFS patients and matched healthy people, making these samples very useful for researchers.

The patient registry will utilise the latest technology available, enabling patients to register and track their symptoms via an app. This will allow researchers to access standardised, anonymous information about patients’ symptoms, which can be analysed for a more detailed understanding of the condition and how symptoms change over time.

Research project

The grant will also support a collaborative research project involving several institutions (see full list below). This project, led by Professor Paul Fisher from La Trobe University, will use the blood samples stored in the biobank and data from the patient registry.

Access to well-characterised samples and ongoing data from the patient registry promises to be an invaluable resource for researchers. We are excited by the potential for this project to help accelerate ME/CFS research in Australia and around the world.

While there have been some recent advances in our understanding of the biomedical basis of ME/CFS, more research needs to be undertaken to find effective diagnostics and treatments for a condition that is still widely misunderstood both by the community in general and by clinical professionals.

Emerge Australia is thrilled to be a part of this initiative and we are immensely grateful for this much-needed funding from the Mason Foundation for establishing the biobank and for supporting further research.

Partner institutions

Chief investigators on the project are Associate Professor Heidi Nicholl, CEO, Emerge Australia and Professor Paul Fisher, La Trobe University.

The full list of co-investigators are:

Australian National University (ANU)
Bio21/University of Melbourne
BC Women’s Hospital in Canada
Emerge Australia
La Trobe University
London School of Hygiene and Tropical Medicine (LSHTM) CureME research group
Macquarie University
Murdoch Children’s Research Institute (MCRI) and Victorian Paediatric Rehabilitation Service
Open Medicine Foundation
Solve ME/CFS Initiative

How can I get involved?

The project is in development at the moment, with operations targeted to launch fully in 2020. You can keep up to date with the specifics of this project - and register your interest to participate - via our dedicated Biobank News mailing list.

Of course, we will also keep all of our subscribers, members and supporters updated via our newsletter, journal, social media (Facebook and Twitter), and on this website.

What is a patient registry?

A patient registry is a database of patients that stores details about their medical history in relation to a particular disease or condition. A registry may be used to identify patients who are willing to take part in research, or the data may be aggregated and used on its own. In the soon to be established Mason Foundation Biobank and patient registry, we plan to partner with Solve ME/CFS and CureME - the London ME/CFS Biobank – to encourage Australian patients to sign up for the registry and to track their symptoms in an app.

Patient registries have been defined as 'an organised system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves a predetermined scientific, clinical, or policy purpose(s).'* In brief, a patient registry is a collection – for one or more purposes – of standardised information about a group of patients who share a condition or experience.

Patient-powered patient registries (PPRs)

PPRs are similar in many ways to researcher-generated patient registries in definition, purpose, and features. At times, these registries are somewhat indistinguishable from traditional registries, with one exception: in patient-powered patient registries, patients and family members 'power' the registry by managing or controlling the collection of the data, the research agenda for the data, and/or the translation and dissemination of the research from the data.

*Workman TA. Engaging Patients in Information Sharing and Data Collection: The Role of Patient-Powered Registries and Research Networks [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Sept, Defining Patient Registries and Research Networks. Available from here.

What is a biobank or tissue bank?

The Mason Foundation-funded biobank will be the storage of donated blood from patients who have consented to the process and who have given details of their medical history. In the future, tissue banking could extend to other tissues and we may collect things like faecal samples, urine, biopsied muscle samples (muscle 'snips') etc.

The main activity of a tissue or biobank is the harvesting, processing, storage and transportation of human tissues for clinical or research use. Low temperature storage of processed tissue is commonly used to preserve the biological data available in the samples. Tissue banking is a complex system and needs high levels of technical expertise and skilled personnel to function properly, and is usually done in a dedicated facility. We will achieve this by partnering with an organisation who have experience with tissue banking while Emerge Australia will co-ordinate both patient recruitment and scientists applying to use the materials.

Strict laws and stringent regulations about collection and storage of human material helps to streamline the process of tissue banking, and also keeps the process safe for donors, researchers and the community as a whole.

[Based on Narayan RP. Development of tissue bank, Indian J Plast Surg. 2012;45(2):396–402. doi:10.4103/0970-0358.101326]

Latest

Terms and Conditions of Purchase
Help us to educate people in power about ME/CFS

Help us to continue to improve our ability to educate people in power and people caring for those with ME/CFS
Research Digest 12/06/20

Welcome to the 49th edition of the Research Digest featuring a study investigating the role that Human herpesvirus 6A may play in ME/CFS pathogenesis and an Australian literature review on metabolomic dysregulation in ME/CFS.
Research Digest 29/05/20

Welcome to the 48th edition of the Research Digest featuring a study that investigates differences in immune gene SNP expression in ME/CFS and a systematic review on neurological impairments as measured by neuroimaging techniques.

Coronavirus and ME - Simplified facts

Many people with ME/CFS and other vulnerable communities in Australia are concerned about the impacts of the spreading coronavirus disease COVID-19. This is an easy-read resource with the latest information and advice.
Research Digest 06/03/20

Welcome to the 42nd edition, featuring a study into a potential clinically-suitable diagnostic biomarker for ME/CFS and a study that furthers our knowledge of the mitochondrial dysfunction exhibited by ME/CFS patients.
Diagnosis

How a diagnosis of myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) is made, the severity scale of ME/CFS, and the importance of early and accurate diagnosis
Accessibility
What is ME/CFS?

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and disabling disease that affects many parts of the body, including the brain and muscles, as well as the digestive, immune and cardiac systems, among others.
Research Digest 03/04/20

Welcome to the 44th edition of the Research Digest. This edition features a recently published book that highlights the value of biomedical research in ME/CFS and a systematic review into the effect of treatment interventions on pain scores in paediatric ME/CFS patients.
Research Digest 20/03/20

Welcome to the 43rd edition of the Research Digest. This fortnight's edition features two studies that investigate new approaches to the way ME/CFS can be diagnosed using microRNA analysis and fMRI.
What is fibromyalgia?

Fibromyalgia is an associated condition of ME/CFS
Research Digest 24/01/20

Welcome to the 39th edition, featuring a systematic review of ME/CFS randomized controlled trials and a study into the use of heart rate variability as a non-invasive biomarker for predicting fatigue severity in ME/CFS patients.
Research Digest 15/05/20

Welcome to the 47th edition of the Research Digest. This fortnight's edition digests a whole brain MRS study looking at metabolite abnormalities in the brains of ME/CFS patients and a French study investigating muscle excitability in exercising and resting muscles of patients diagnosed with ME/CFS.